Hopital Cochin Saint Vincent de Paul

Saint-Vincent-de-Paul, France

Hopital Cochin Saint Vincent de Paul

Saint-Vincent-de-Paul, France
SEARCH FILTERS
Time filter
Source Type

Rouzier R.,University Pierre and Marie Curie | Werkoff G.,Hopital Tenon | Werkoff G.,University Pierre and Marie Curie | Uzan C.,Institut Universitaire de France | And 8 more authors.
Annals of Oncology | Year: 2011

Background: The aim of this study was to determine the chemosensitivity of pregnancy-associated breast cancer (PABC) in the neoadjuvant setting by comparing the observed pathological complete response (pCR) rate with the rate predicted by a validated nomogram. Methods: Data from 48 PABC patients who received neoadjuvant chemotherapy (NACT) were collected. To predict the response rate to chemotherapy, we used well-calibrated logistic regression-based nomograms to calculate individual probability of pCR. Results: Observed rates of pCR were concordant with predictions in the whole sample and in the analyzed subgroups. For the whole sample, the area under the receiver-operated curve (AUC) was 0.77 (95% CI 0.66-0.87). The calibration of predicted and observed probabilities was excellent. In the subgroup analyses (NACT initiated during pregnancy or postpartum, NACT with only anthracycline or both anthracycline and taxanes), discriminations assessed by AUC were significantly above 0.5, except for patients treated with anthracycline only. The interpretation was limited by a lack of power. Conclusion: Through the use of nomograms, our study demonstrates that PABC is as chemosensitive as non-PABC and suggests that taxanes should be part of the NACT regimen for PABC. Further studies are warranted to increase the power of the presented data. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.


Wucher H.,University of Paris Descartes | Lepercq J.,University of Paris Descartes | Carette C.,University of Paris Descartes | Colas C.,Hotel Dieu | And 11 more authors.
Diabetes and Metabolism | Year: 2011

Aim: To describe the clinical presentation and the prognosis of autoimmune type 1 diabetes (T1D) that was first revealed during pregnancy masquerading as gestational diabetes mellitus (GDM). Methods: We reviewed the files of 21 women in whom diabetes was revealed during a pregnancy (" index pregnancy" ) and progressed to T1D after delivery, and in whom GAD and/or IA-2 autoantibodies were found. Results: The median age and BMI of the women were 31 years and 19.8kg/m2. Eleven women had at least one risk factor for GDM. Eight of the 12 multiparous women had had an abnormal outcome of previous pregnancy, including GDM in five. GDM was diagnosed at week 26 (range: 4-38) of gestation by screening in 18, because of macrosomia in two and during hyperglycaemic crises in three. All were treated with insulin, from the time of diabetes diagnosis in 10 and after 4 weeks (range: 2-15) in 11. Term of delivery was 38 (range: 26-41) weeks. Abnormal outcomes occured in 14 pregnancies, including two fetal deaths, four preterm deliveries and eight macrosomic infants. No congenital malformations were reported. After delivery, insulin therapy was stopped in 18 women for 6 months (range: 2-48). The diagnosis of the autoimmune origin of diabetes was established during the index pregnancy in only eight cases. Conclusion: T1D may reveal as GDM in women with or without risk factors for GDM and is associated with a poor prognosis, partly because the correct diagnosis and treatment are delayed. Whether screening for autoimmune markers of T1D should be performed more systematically in women with GDM deserves to be studied. © 2010.

Loading Hopital Cochin Saint Vincent de Paul collaborators
Loading Hopital Cochin Saint Vincent de Paul collaborators